Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Unusual 'ingredients' helped stars form in a galaxy near the Milky Way - 2Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up
- 3The most effective method to Pick The Right Speakers
- 4Behind every perfect holiday memory is a mom on the brink
- 5Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
- Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- The most effective method to Remain Ahead in the Most recent Advanced Patterns with a Web based Advertising Degree
- Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter
- The most effective method to Apply Antiquated Ways of thinking in Current Brain science Practices
- Was it a stone tool or just a rock? An archaeologist explains how scientists can tell the difference
- Dominating Capable Mastercard Utilization: Key Contemplations
- Track down the Ideal Weight reduction Methodology for Your Way of life
- Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
